shortagewatch

Home / Nervous system / Levodopa and Decarboxylase Inhibitor

ATC N04BA02 · Dopa and Dopa Derivatives

Levodopa and Decarboxylase Inhibitor shortage

As of 2 Nov 2026, Levodopa and Decarboxylase Inhibitor has a reported shortage in 4 of the 16 countries we track (Canada, Czechia, Norway, Sweden), covering 9 products from 6 companies.

Countries4/16
Products9packs or presentations
Companies63 listed
Short since28 Nov 20196.9 years ago
Earliest return6 Nov 2026company estimate
Main reasonManufacturing problem
United StatesNo reported shortageCanada6 products shortGermanyNo reported shortageFranceNo reported shortageItalyNo reported shortageSpainNo reported shortageIrelandNo reported shortageAustriaNo reported shortageBelgiumNo reported shortageSwitzerlandNo reported shortageCzechia1 product shortNorway1 product shortSweden1 product shortJapanNo reported shortageNew ZealandNo reported shortageAustraliaNo reported shortage

Timeline

CanadaCzechiaNorwaySweden
202220232024202520262028TEVA-LEVOCARBIDOPA (100)TEVA-LEVOCARBIDOPA (100)TEVA-LEVOCARBIDOPA (500)TEVA-LEVOCARBIDOPA (500)TEVA-LEVOCARBIDOPA (100)TEVA-LEVOCARBIDOPA (100)TEVA-LEVOCARBIDOPA (100)TEVA-LEVOCARBIDOPA (100)MINT-LEVOCARB (100 count bottles)MINT-LEVOCARB (100 count bottles)AA-LEVOCARB CR (100 BTL)AA-LEVOCARB CR (100 BTL)NAKOM 250MG/25MG 250MG/25MG TBL NOB 100NAKOM 250MG/25MG 250MG/25MG TBL NOB 100Sinemet 25/100 25 mg/100 mg tablett, 100 stkSinemet 25/100 25 mg/100 mg tablett, 100 stk boksCarbidopa/Levodopa Orifarm 25 mg/100 mg BlisCarbidopa/Levodopa Orifarm 25 mg/100 mg Blister, 100 tablettertoday

Solid bars run from the reported start to today; faded bars show the time left until the expected return. An arrow means no return date was given.

Which companies are short

products short, all countries
Teva4 TEVAMint Pharmaceuticals1AA Pharma1Sandoz1 SDZOrganon1 OGNOrifarm1

Listed: Teva TEVA · NYSE / TASE, Sandoz SDZ · SIX Swiss, Organon OGN · NYSE

Compared with similar medicines

ATC group N04BA · Dopa and Dopa Derivatives
Levodopa and Decarboxylase Inhibitor4/16Levodopa, Decarboxylase Inhibitor and COMT Inhibitor4/16

Affected products

CountryProductCompanySinceExpected backReason
CATEVA-LEVOCARBIDOPA (100)TEVA CANADA LIMITED28 Nov 2019not givenManufacturing problem
Disruption of the manufacture of the drug
CATEVA-LEVOCARBIDOPA (500)TEVA CANADA LIMITED4 Dec 2019not givenManufacturing problem
Disruption of the manufacture of the drug
CATEVA-LEVOCARBIDOPA (100)TEVA CANADA LIMITED20 Feb 2020not givenManufacturing problem
Disruption of the manufacture of the drug
CATEVA-LEVOCARBIDOPA (100)TEVA CANADA LIMITED25 Mar 2020not givenManufacturing problem
Disruption of the manufacture of the drug
CAMINT-LEVOCARB (100 count bottles)MINT PHARMACEUTICALS INC8 Dec 202030 Nov 2026Manufacturing problem
Requirements related to complying with good manufacturing practices
CAAA-LEVOCARB CR (100 BTL)AA PHARMA INC6 Oct 20266 Nov 2026Manufacturing problem
Disruption of the manufacture of the drug
CZNAKOM 250MG/25MG 250MG/25MG TBL NOB 100Lek Pharmaceuticals d.d., Ljubljana2 Sep 202620 Nov 2026Distribution or logistics
Kapacitní/distribuční důvody
NOSinemet 25/100 25 mg/100 mg tablett, 100 stk boksN.V. Organon - Kloosterstraat15 Sep 20268 Nov 2026Manufacturing problem
Produksjonsproblemer
SECarbidopa/Levodopa Orifarm 25 mg/100 mg Blister, 100 tabletterOrifarm Healthcare A/S1 May 202630 Jun 2027Not stated

"Expected back" is the date the company gave the authority, when it gave one. Ask a pharmacist about alternatives.